Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study

BACKGROUND: Survival for pancreatic ductal adenocarcinoma is low, the role of adjuvant therapy remains controversial, and recent data suggest adjuvant chemoradiation (CRT) may decrease survival compared with surgery alone. Our goal was to examine efficacy of adjuvant CRT in resected pancreatic adeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Charles C., Herman, Joseph M., Corsini, Michele M., Winter, Jordan M., Callister, Matthew D., Haddock, Michael G., Cameron, John L., Pawlik, Timothy M., Schulick, Richard D., Wolfgang, Christopher L., Laheru, Daniel A., Farnell, Michael B., Swartz, Michael J., Gunderson, Leonard L., Miller, Robert C.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Pancreatic Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840672/
https://www.ncbi.nlm.nih.gov/pubmed/20087786
http://dx.doi.org/10.1245/s10434-009-0743-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840672/
https://www.ncbi.nlm.nih.gov/pubmed/20087786
http://dx.doi.org/10.1245/s10434-009-0743-7

Ejemplares similares